 Ocular Therapeutix Inc NASDAQ: OCUL has dosed the first patient in its Phase 2 trial evaluating OTX-DED dexamethasone intracanalicular ophthalmic insert for the short-term treatment of the signs and symptoms of dry eye disease. OTX-DED is a physician-administered, preservative-free intracanalicular insert designed to deliver either 0.2 or 0.3 mg doses of dexamethasone. 